Aurobindo Acquires Seven Oncology Injectables From Spectrum

In line with its strategy to establish its presence in the US branded market, Aurobindo has through its subsidiary Acrotech Biopharma acquired seven marketed oncology injectables from Spectrum Pharmaceuticals in a deal worth up to US$300 million.

Syringes
Aurobindo has acquired seven oncology injectables from Spectrum • Source: Shutterstock

Aurobindo is set to expand its presence in the US branded market after snapping up through its Acrotech Biopharma subsidiary seven marketed oncology injectable products from Spectrum Pharmaceuticals.

For an upfront purchase price of US$160 million in cash, plus up to US$140 million in regulatory and sales-based milestones,...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business